BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 9335524)

  • 1. The substrate binding site of human liver cytochrome P450 2C9: an NMR study.
    Poli-Scaife S; Attias R; Dansette PM; Mansuy D
    Biochemistry; 1997 Oct; 36(42):12672-82. PubMed ID: 9335524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9.
    Mancy A; Dijols S; Poli S; Guengerich P; Mansuy D
    Biochemistry; 1996 Dec; 35(50):16205-12. PubMed ID: 8973193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of new sulfaphenazole derivatives with human liver cytochrome p450 2Cs: structural determinants required for selective recognition by CYP 2C9 and for inhibition of human CYP 2Cs.
    Ha-Duong NT; Marques-Soares C; Dijols S; Sari MA; Dansette PM; Mansuy D
    Arch Biochem Biophys; 2001 Oct; 394(2):189-200. PubMed ID: 11594733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid.
    Melet A; Assrir N; Jean P; Pilar Lopez-Garcia M; Marques-Soares C; Jaouen M; Dansette PM; Sari MA; Mansuy D
    Arch Biochem Biophys; 2003 Jan; 409(1):80-91. PubMed ID: 12464247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase).
    Jones BC; Hawksworth G; Horne VA; Newlands A; Morsman J; Tute MS; Smith DA
    Drug Metab Dispos; 1996 Feb; 24(2):260-6. PubMed ID: 8742240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the substrate specificities of human liver cytochrome P450s 2C9 and 2C18: application to the design of a specific substrate of CYP 2C18.
    Minoletti C; Dijols S; Dansette PM; Mansuy D
    Biochemistry; 1999 Jun; 38(24):7828-36. PubMed ID: 10387023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding.
    Haining RL; Jones JP; Henne KR; Fisher MB; Koop DR; Trager WF; Rettie AE
    Biochemistry; 1999 Mar; 38(11):3285-92. PubMed ID: 10079071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrospray ionization mass spectrometric analysis of intact cytochrome P450: identification of tienilic acid adducts to P450 2C9.
    Koenigs LL; Peter RM; Hunter AP; Haining RL; Rettie AE; Friedberg T; Pritchard MP; Shou M; Rushmore TH; Trager WF
    Biochemistry; 1999 Feb; 38(8):2312-9. PubMed ID: 10029524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac.
    Tang W; Stearns RA; Wang RW; Chiu SH; Baillie TA
    Chem Res Toxicol; 1999 Feb; 12(2):192-9. PubMed ID: 10027798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling.
    Mancy A; Broto P; Dijols S; Dansette PM; Mansuy D
    Biochemistry; 1995 Aug; 34(33):10365-75. PubMed ID: 7654690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxydiclofenac.
    Shen S; Marchick MR; Davis MR; Doss GA; Pohl LR
    Chem Res Toxicol; 1999 Feb; 12(2):214-22. PubMed ID: 10027801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A model for human cytochrome P450 2D6 based on homology modeling and NMR studies of substrate binding.
    Modi S; Paine MJ; Sutcliffe MJ; Lian LY; Primrose WU; Wolf CR; Roberts GC
    Biochemistry; 1996 Apr; 35(14):4540-50. PubMed ID: 8605204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.
    Haining RL; Hunter AP; Veronese ME; Trager WF; Rettie AE
    Arch Biochem Biophys; 1996 Sep; 333(2):447-58. PubMed ID: 8809086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opposite behaviors of reactive metabolites of tienilic acid and its isomer toward liver proteins: use of specific anti-tienilic acid-protein adduct antibodies and the possible relationship with different hepatotoxic effects of the two compounds.
    Bonierbale E; Valadon P; Pons C; Desfosses B; Dansette PM; Mansuy D
    Chem Res Toxicol; 1999 Mar; 12(3):286-96. PubMed ID: 10077492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.
    He M; Korzekwa KR; Jones JP; Rettie AE; Trager WF
    Arch Biochem Biophys; 1999 Dec; 372(1):16-28. PubMed ID: 10562412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs.
    Mancy A; Antignac M; Minoletti C; Dijols S; Mouries V; Duong NT; Battioni P; Dansette PM; Mansuy D
    Biochemistry; 1999 Oct; 38(43):14264-70. PubMed ID: 10572000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidation of tienilic acid by human yeast-expressed cytochromes P-450 2C8, 2C9, 2C18 and 2C19. Evidence that this drug is a mechanism-based inhibitor specific for cytochrome P-450 2C9.
    Jean P; Lopez-Garcia P; Dansette P; Mansuy D; Goldstein JL
    Eur J Biochem; 1996 Nov; 241(3):797-804. PubMed ID: 8944768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.
    Ha-Duong NT; Dijols S; Marques-Soares C; Minoletti C; Dansette PM; Mansuy D
    J Med Chem; 2001 Oct; 44(22):3622-31. PubMed ID: 11606127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effector-mediated alteration of substrate orientation in cytochrome P450 2C9.
    Hummel MA; Gannett PM; Aguilar JS; Tracy TS
    Biochemistry; 2004 Jun; 43(22):7207-14. PubMed ID: 15170358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydrophobic side chain requirements for lauric acid and progesterone hydroxylation at amino acid 113 in cytochrome P450 2C2, a potential determinant of substrate specificity.
    Straub P; Johnson EF; Kemper B
    Arch Biochem Biophys; 1993 Nov; 306(2):521-7. PubMed ID: 8215458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.